KR102914926B1 - 피리미딘 화합물의 결정 - Google Patents

피리미딘 화합물의 결정

Info

Publication number
KR102914926B1
KR102914926B1 KR1020237003585A KR20237003585A KR102914926B1 KR 102914926 B1 KR102914926 B1 KR 102914926B1 KR 1020237003585 A KR1020237003585 A KR 1020237003585A KR 20237003585 A KR20237003585 A KR 20237003585A KR 102914926 B1 KR102914926 B1 KR 102914926B1
Authority
KR
South Korea
Prior art keywords
crystal
compound
leu
pro
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237003585A
Other languages
English (en)
Korean (ko)
Other versions
KR20230034341A (ko
Inventor
히로유키 나카무라
히로요시 야마나카
다카히로 아사이
Original Assignee
다이호야쿠힌고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이호야쿠힌고교 가부시키가이샤 filed Critical 다이호야쿠힌고교 가부시키가이샤
Publication of KR20230034341A publication Critical patent/KR20230034341A/ko
Application granted granted Critical
Publication of KR102914926B1 publication Critical patent/KR102914926B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Liquid Crystal Substances (AREA)
KR1020237003585A 2020-07-15 2021-07-14 피리미딘 화합물의 결정 Active KR102914926B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2020-121520 2020-07-15
JP2020121520 2020-07-15
PCT/JP2021/026460 WO2022014638A1 (ja) 2020-07-15 2021-07-14 ピリミジン化合物の結晶

Publications (2)

Publication Number Publication Date
KR20230034341A KR20230034341A (ko) 2023-03-09
KR102914926B1 true KR102914926B1 (ko) 2026-01-19

Family

ID=79554693

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237003585A Active KR102914926B1 (ko) 2020-07-15 2021-07-14 피리미딘 화합물의 결정

Country Status (12)

Country Link
US (1) US12492208B2 (https=)
EP (1) EP4183788A4 (https=)
JP (1) JP7391226B2 (https=)
KR (1) KR102914926B1 (https=)
CN (1) CN116249534B (https=)
AU (1) AU2021307245B2 (https=)
BR (1) BR112023000765A2 (https=)
MX (1) MX2023000692A (https=)
MY (1) MY207540A (https=)
PH (1) PH12023550116A1 (https=)
TW (1) TWI905228B (https=)
WO (1) WO2022014638A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4351737A4 (en) * 2021-05-24 2025-05-14 Taiho Pharmaceutical Co., Ltd. Treatment methods for subjects with cancer having an aberration in egfr and/or her2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065898A2 (en) 2008-12-05 2010-06-10 Principia Biopharma Inc. Egfr kinase knockdown via electrophilically enhanced inhibitors
WO2013118817A1 (ja) 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
WO2017038838A1 (ja) 2015-09-01 2017-03-09 大鵬薬品工業株式会社 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩
WO2020145374A1 (ja) 2019-01-11 2020-07-16 大鵬薬品工業株式会社 ピリミジン化合物又はその塩

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101852738B1 (ko) * 2015-01-30 2018-04-27 다이호야쿠힌고교 가부시키가이샤 축합 피리미딘 화합물의 신규한 염 및 그 결정
JP6537601B2 (ja) * 2015-05-12 2019-07-03 大鵬薬品工業株式会社 アザ二環式化合物の結晶
KR102674711B1 (ko) * 2017-02-28 2024-06-12 다이호야쿠힌고교 가부시키가이샤 피라졸로[3,4-d]피리미딘 화합물을 사용한 항종양 효과 증강제
WO2020004546A1 (ja) 2018-06-28 2020-01-02 日本電気株式会社 遠隔制御装置、遠隔制御方法及びプログラム
MA53509A (fr) 2018-08-29 2021-07-07 Taiho Pharmaceutical Co Ltd Agent thérapeutique contenant un composé pyrazolo[3,4-d]pyrimidine comme ingrédient actif
JP7164455B2 (ja) 2019-01-31 2022-11-01 理想科学工業株式会社 容器
EP4183395A4 (en) 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
MX2023000693A (es) 2020-07-15 2023-02-13 Taiho Pharmaceutical Co Ltd Inhibidor de egfr.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010065898A2 (en) 2008-12-05 2010-06-10 Principia Biopharma Inc. Egfr kinase knockdown via electrophilically enhanced inhibitors
WO2013118817A1 (ja) 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
WO2017038838A1 (ja) 2015-09-01 2017-03-09 大鵬薬品工業株式会社 新規なピラゾロ［３，４－ｄ］ピリミジン化合物又はその塩
WO2020145374A1 (ja) 2019-01-11 2020-07-16 大鵬薬品工業株式会社 ピリミジン化合物又はその塩

Also Published As

Publication number Publication date
TWI905228B (zh) 2025-11-21
JP7391226B2 (ja) 2023-12-04
JPWO2022014638A1 (https=) 2022-01-20
US20230331730A1 (en) 2023-10-19
KR20230034341A (ko) 2023-03-09
MX2023000692A (es) 2023-02-13
CA3189457A1 (en) 2022-01-20
US12492208B2 (en) 2025-12-09
PH12023550116A1 (en) 2024-06-24
WO2022014638A1 (ja) 2022-01-20
BR112023000765A2 (pt) 2023-02-07
CN116249534A (zh) 2023-06-09
EP4183788A1 (en) 2023-05-24
MY207540A (en) 2025-03-04
TW202216717A (zh) 2022-05-01
CN116249534B (zh) 2025-03-25
EP4183788A4 (en) 2024-07-17
AU2021307245B2 (en) 2024-02-29
AU2021307245A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
KR102873219B1 (ko) Egfr 저해제
US11485726B2 (en) Compound for inhibiting and degrading tyrosine protein kinase ALK
TWI623533B (zh) 作為檢測點激酶1 (chk1)抑制劑之3,5-二取代吡唑及其製備及應用
KR102640463B1 (ko) 피리미딘 화합물 또는 그 염
WO2020027083A1 (ja) キナゾリン化合物を有効成分とする医薬組成物
HUE027534T2 (en) Notch pathway inhibitory compound
JP2025512920A (ja) ヘテロ芳香族大環状エーテル化合物の固体形態、薬学的組成物、及び調製
KR102914926B1 (ko) 피리미딘 화합물의 결정
JP7054528B2 (ja) プロテインキナーゼ活性を抑制する化合物の結晶形態、及びその適用
CA3189457C (en) Crystal of pyrimidine compound
RU2828232C1 (ru) Кристалл соединения пиримидина
HK40087564B (zh) 嘧啶化合物的结晶
HK40087564A (zh) 嘧啶化合物的结晶
RU2787992C1 (ru) Пиримидиновое соединение или его соль
HK40056369A (en) Pyrimidine compound or salt thereof
WO2016050016A1 (zh) 作为激酶抑制剂的取代杂环化合物及其制备方法和用途
HK40056369B (zh) 嘧啶化合物或其盐
WO2016052081A1 (ja) 癌細胞増殖抑制剤、抗癌剤、及びこれらのスクリーニング方法、並びに新規化合物

Legal Events

Date Code Title Description
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)